Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Reporting Period: As of December 31, 2025, with subsequent events through January 7, 2026.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $71.8 million as of December 31, 2025 (unaudited and preliminary).
- Recent Proceeds: Approximately $26.5 million received from the exercise of common stock warrants subsequent to December 31, 2025.
- Shares Outstanding: 170,282,026 shares as of January 7, 2026.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Debt and Liquidity: Specific debt figures are not provided; liquidity is indicated by the cash position and recent warrant proceeds.
Material Changes
The primary material change reported is the receipt of approximately $26.5 million in cash proceeds from the exercise of common stock warrants occurring after the December 31, 2025 balance sheet date. This event has increased the company's cash position relative to the preliminary year-end estimate.
Guidance, Outlook, and Risks
- Management Commentary: The $71.8 million cash position as of December 31, 2025, is unaudited and preliminary. Management notes this amount is subject to completion of financial closing procedures and may differ materially from final audited financial statements.
- Risks and Contingencies: The filing highlights the risk of material variance between the preliminary cash estimate and the final audited figures.
- Guidance: No specific forward-looking guidance or outlook is provided in this filing.
Investor Verification Checklist
- Verify the final audited cash and cash equivalents balance for the year ended December 31, 2025, once the annual report is filed.
- Confirm the total number of shares outstanding following the warrant exercises and any subsequent issuances.
- Review the full 10-K filing for detailed revenue, operating expenses, and net loss figures not included in this 8-K.
- Assess the impact of the $26.5 million warrant proceeds on the company's runway and capital allocation strategy.